• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.

作者信息

Rovina Nikoletta, Akinosoglou Karolina, Eugen-Olsen Jesper, Hayek Salim, Reiser Jochen, Giamarellos-Bourboulis Evangelos J

机构信息

1st Department of Pulmonary Medicine and Intensive Care Unit, National and Kapodistrian University of Athens, Medical School, 115 27, Athens, Greece.

Department of Internal Medicine, University of Patras, Medical School, 265 04, Rio, Greece.

出版信息

Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.

DOI:10.1186/s13054-020-02897-4
PMID:32354367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7191969/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f525/7193381/55a8fd90a8d1/13054_2020_2897_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f525/7193381/55a8fd90a8d1/13054_2020_2897_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f525/7193381/55a8fd90a8d1/13054_2020_2897_Fig1_HTML.jpg

相似文献

1
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.可溶性尿激酶型纤溶酶原激活物受体（suPAR）作为新型冠状病毒肺炎患者严重呼吸衰竭的早期预测指标
Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.
2
Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.可溶性尿激酶型纤溶酶原激活物受体（SuPAR）与 COVID-19 相关急性肾损伤。
J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. doi: 10.1681/ASN.2020060829. Epub 2020 Sep 22.
3
Supportive treatment of COVID 19 patients with mild respiratory failure in a primary hospital.基层医院对轻度呼吸衰竭的新冠病毒肺炎患者的支持性治疗。
Med Clin (Barc). 2020 Sep 11;155(5):222-223. doi: 10.1016/j.medcli.2020.06.008. Epub 2020 Jun 11.
4
COVID-19 or common coronavirus? A cautionary tale in advanced diagnostics.新冠病毒还是普通冠状病毒？先进诊断中的一则警示故事。
Diagnosis (Berl). 2020 Nov 18;7(4):345-346. doi: 10.1515/dx-2020-0093.
5
Respiratory failure alone does not suggest central nervous system invasion by SARS-CoV-2.单纯的呼吸衰竭并不提示新型冠状病毒严重急性呼吸综合征冠状病毒2侵犯中枢神经系统。
J Med Virol. 2020 Jul;92(7):705-706. doi: 10.1002/jmv.25828. Epub 2020 Apr 24.
6
Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients.新冠病毒肺炎患者中可溶性尿激酶型纤溶酶原激活物受体（suPAR）升高。
Clin Chem Lab Med. 2021 Jun 14;59(11):e413-e415. doi: 10.1515/cclm-2021-0561. Print 2021 Oct 26.
7
Serial serum SARS-CoV-2 RNA results in two COVID-19 cases with severe respiratory failure.两例患有严重呼吸衰竭的新型冠状病毒肺炎病例的系列血清严重急性呼吸综合征冠状病毒2核糖核酸检测结果
J Infect Chemother. 2020 Nov;26(11):1220-1223. doi: 10.1016/j.jiac.2020.07.003. Epub 2020 Jul 17.
8
Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.重症 COVID-19 患者的生物标志物与早发性急性肾损伤：一项前瞻性单中心观察性研究
BMC Nephrol. 2025 Jul 1;26(1):294. doi: 10.1186/s12882-025-04267-0.
9
Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation.快速 COVID-19 严重程度指数的制定与验证：一种用于早期临床失代偿的预后工具。
Ann Emerg Med. 2020 Oct;76(4):442-453. doi: 10.1016/j.annemergmed.2020.07.022. Epub 2020 Jul 21.
10
An open label trial of anakinra to prevent respiratory failure in COVID-19.阿那白滞素预防 COVID-19 呼吸衰竭的开放标签试验。
Elife. 2021 Mar 8;10:e66125. doi: 10.7554/eLife.66125.

引用本文的文献

1
Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.重症 COVID-19 患者的生物标志物与早发性急性肾损伤：一项前瞻性单中心观察性研究
BMC Nephrol. 2025 Jul 1;26(1):294. doi: 10.1186/s12882-025-04267-0.
2
29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial.用于COVID-19肺炎中细菌感染、病毒感染和疾病进展分类的29种mRNA宿主反应特征：SAVE-MORE随机临床试验的事后分析
Intensive Care Med Exp. 2025 Jun 30;13(1):67. doi: 10.1186/s40635-025-00777-1.
3

本文引用的文献

1
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
2
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
3
Soluble Urokinase Receptor and Acute Kidney Injury.可溶性尿激酶型纤溶酶原激活物受体与急性肾损伤
The dynamic role of soluble urokinase plasminogen activator receptor (suPAR) in monitoring coagulation dysfunction during COVID-19 progression: a review.
可溶性尿激酶型纤溶酶原激活物受体（suPAR）在监测新型冠状病毒肺炎（COVID-19）进展过程中凝血功能障碍的动态作用：综述
Ann Med Surg (Lond). 2024 Dec 19;87(2):635-640. doi: 10.1097/MS9.0000000000002791. eCollection 2025 Feb.
4
Advances in Understanding Inflammation and Tissue Damage: Markers of Persistent Sequelae in COVID-19 Patients.炎症与组织损伤认识的进展：COVID-19患者持续性后遗症的标志物
J Clin Med. 2025 Feb 22;14(5):1475. doi: 10.3390/jcm14051475.
5
Soluble Urokinase Plasminogen Activator Receptor: A Promising Biomarker for Mortality Prediction Among Critical ED Patients.可溶性尿激酶型纤溶酶原激活物受体：急诊重症患者死亡率预测的一种有前景的生物标志物。
Int J Mol Sci. 2025 Feb 13;26(4):1609. doi: 10.3390/ijms26041609.
6
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial.巴瑞替尼在接种疫苗的重症和危重症COVID-19患者中的安全性——随机Bari-SolidAct试验的子研究
EBioMedicine. 2025 Jan;111:105511. doi: 10.1016/j.ebiom.2024.105511. Epub 2024 Dec 27.
7
Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients.可溶性尿激酶型纤溶酶原激活物受体：预测COVID-19患者死亡率的有用标志物。
Cureus. 2024 Nov 25;16(11):e74438. doi: 10.7759/cureus.74438. eCollection 2024 Nov.
8
Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.新冠病毒肺炎患者可溶性尿激酶型纤溶酶原激活物受体的评估
J Clin Med. 2024 Oct 23;13(21):6340. doi: 10.3390/jcm13216340.
9
Post-COVID-19 Multisystem Inflammatory Syndrome in Adults (MIS-A) With Elevated Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Treated With Anakinra: A Case Report.托珠单抗治疗成人新冠后多系统炎症综合征（MIS-A）伴可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平升高：一例报告
Cureus. 2024 Oct 4;16(10):e70848. doi: 10.7759/cureus.70848. eCollection 2024 Oct.
10
Host Response Markers of Inflammation and Endothelial Activation Associated with COVID-19 Severity and Mortality: A GeoSentinel Prospective Observational Cohort.与 COVID-19 严重程度和死亡率相关的宿主炎症反应标志物和血管内皮激活：GeoSentinel 前瞻性观察队列研究。
Viruses. 2024 Oct 15;16(10):1615. doi: 10.3390/v16101615.
N Engl J Med. 2020 Jan 30;382(5):416-426. doi: 10.1056/NEJMoa1911481.
4
Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy.基于可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平的急诊科提前出院：TRIAGE III 子研究。
Dis Markers. 2019 May 19;2019:3403549. doi: 10.1155/2019/3403549. eCollection 2019.
5
Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.脓毒症中的风险评估：基于急性生理与慢性健康状况评分系统II（APACHE II）评分和血清可溶性尿激酶型纤溶酶原激活剂受体的新预后规则
Crit Care. 2012 Aug 8;16(4):R149. doi: 10.1186/cc11463.
6
Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore).通过表面等离子体共振（BiaCore）技术测定高分子量激肽原与内皮细胞结合蛋白 suPAR、gC1qR 和细胞角蛋白 1 的相互作用。
Thromb Haemost. 2011 Jun;105(6):1053-9. doi: 10.1160/TH10-09-0591. Epub 2011 May 5.